Emerging therapy options for IgG4-related disease

References

• Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. BMJ 2020;369:m1067.
   PubMedGoogle Scholar
• Bledsoe JR, Della-Torre E, Rovati L, et al. IgG4-related disease: review of the histopathologic features, differential diagnosis, and therapeutic approach. APMIS. 2018;126(6):459–476. .
   PubMed Web of Science ®Google Scholar
• Hamano H, Kawa S, Horiuchi A,H, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med. 2001;344(10):732–738. .
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Lanzillotta M, Doglioni C. Immunology of IgG4-related disease. Clin Exp Immunol. 2015;181(2):191–206.
   PubMed Web of Science ®Google Scholar
• Culver EL, Chapman RW. IgG4-related hepatobiliary disease: an overview. Nature Reviews Gastroenterology & Hepatology. 2016;13(10):601–612.
   PubMed Web of Science ®Google Scholar
• Ebbo M, Daniel L, Pavic M, et al. IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore). 2012;91(1):49–56.
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Ramirez GA, Bozzolo EP, et al. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scandinavian Journal of Rheumatology. 2016;45(2):135–145.
   PubMed Web of Science ®Google Scholar
• Fernández-Codina A, Martínez-Valle F, Pinilla B, et al. IgG4-Related Disease: results From a Multicenter Spanish Registry. Medicine (Baltimore). 2015;94(32):e1275. .
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Lanzillotta M, Campochiaro C, et al. Antineutrophil cytoplasmic antibody positivity in IgG4-related disease. Medicine (Baltimore). 2016;95(34):e4633. .
   PubMed Web of Science ®Google Scholar
• Lanzillotta M, Campochiaro C, Trimarchi M, et al. Deconstructing IgG4-related disease involvement of midline structures: comparison to common mimickers. Modern Rheumatology. 2017;27(4):638–645. .
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Mattoo H, Mahajan VS, et al. IgG4-related midline destructive lesion. Ann Rheum Dis. 2014;73(7):1434–1436. .
   PubMed Web of Science ®Google Scholar
• Reder L, Della-Torre E, Stone JH, et al. Clinical Manifestations of IgG4-Related Disease in the Pharynx: case Series and Review of the Literature. Annals of Otology, Rhinology & Laryngology. 2015;124(3):173–178. .
   PubMed Web of Science ®Google Scholar
• Lu LX, Della-Torre E, Stone JH, et al. IgG4-related hypertrophic pachymeningitis: clinical features, diagnostic criteria, and treatment. JAMA Neurology. 2014;71(6):785–793. .
   PubMed Web of Science ®Google Scholar
• Berti A, Della-Torre E, Gallivanone F, et al. Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology (Oxford). 2017;56(12):2084–2092. .
   PubMed Web of Science ®Google Scholar
• Della TE, Bozzolo EP, Passerini G, et al. IgG4-related pachymeningitis: evidence of intrathecal IgG4 on cerebrospinal fluid analysis. Ann Intern Med. 2012;156(5):401–3.
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Galli L, Franciotta D, et al. Diagnostic value of IgG4 Indices in IgG4-related hypertrophic pachymeningitis. Journal of Neuroimmunology. 2014;266(1–2):82–86. .
   PubMed Web of Science ®Google Scholar
• Kanno A, Nishimori I, Masamune A, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan. Pancreas 2012;41(6):835–839.
   PubMed Web of Science ®Google Scholar
• Masamune A, Kikuta K, Hamada S, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016. J Gastroenterol. 2020;55(4):462–470.
   PubMed Web of Science ®Google Scholar
• Uchida K, Masamune A, Shimosegawa T, et al. Prevalence of IgG4-Related Disease in Japan Based on Nationwide Survey in 2009. International Journal of Rheumatology. 2012;2012:358371.
   PubMedGoogle Scholar
• Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Modern Pathology. 2012;25(9):1181–1192. .
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Khosroshahi A, Carruthers MD, et al. An International Multispecialty Validation Study of the IgG4-Related Disease Responder Index. Arthritis Care & Research. 2018;70(11):1671–1678. .
   PubMed Web of Science ®Google Scholar
• Khosroshahi A, Wallace ZS, Crowe JL, et al., International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol. 67(7): 1688–1699. 2015. .
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Naden RP, Chari S, et al. American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol. 2019. 2019. 10.1002/art.41120.
   Web of Science ®Google Scholar
• Wallace ZS, Naden RP, Chari S, et al. American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis. 2019;pii:annrheumdis-2019-216561. 2019.
   Google Scholar
• Wallace ZS, Zhang Y, Perugino CA, et al., Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Annals of the Rheumatic Diseases. 78(3): 406–412. 2019. .
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Rigamonti E, Perugino C, et al. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. J Allergy Clin Immunol. 2020;145(3):e14. .
   Web of Science ®Google Scholar
• Mattoo H, Mahajan VS, Maehara T, et al. Clonal expansion of CD4 + cytotoxic T lymphocytes in patients with IgG 4 -related disease. Journal of Allergy and Clinical Immunology. 2016;138(3):825–838. .
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Feeney E, Deshpande V, et al. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Annals of the Rheumatic Diseases. 2015;74(12):2236–2243. .
   PubMed Web of Science ®Google Scholar
• Mattoo H, Mahajan VS, Della-Torre E, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease. Journal of Allergy and Clinical Immunology. 2014;134(3):679–687. .
   PubMed Web of Science ®Google Scholar
• Perugino CA, Kaneko N, Maehara T, et al. CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease. J Allergy Clin Immunol. 2021;147(1):368-382.
   PubMed Web of Science ®Google Scholar
• Grados A, Ebbo M, Piperoglou C, et al. T Cell Polarization toward TH2/TFH2 and TH17/TFH17 in Patients with IgG4-Related Disease. Frontiers in Immunology. 2017;8:235.
   PubMed Web of Science ®Google Scholar
• Cargill T, Makuch M, Sadler R, et al. Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-Related Sclerosing Cholangitis and Pancreatitis. Clinical and Translational Gastroenterology. 2019;10(4):e00020. .
   PubMedGoogle Scholar
• Cargill T, Barnes E, Culver EL. Expansion of a Novel Subset of PD1+CXCR5-CD4+ T Peripheral Helper Cells in IgG4-Related Disease. Clinical and Translational Gastroenterology. 2020;11(1):e00111.
   PubMedGoogle Scholar
• Della-Torre E, Stone JH. “How I manage” IgG4-Related Disease. J Clin Immunol. 2016;36(8):754–763.
   PubMed Web of Science ®Google Scholar
• Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology (Oxford). 2020;59(9):2435–2442.
   PubMed Web of Science ®Google Scholar
• Lanzillotta M, Della-Torre E, Stone JH. Roles of Plasmablasts and B Cells in IgG4-Related Disease: implications for Therapy and Early Treatment Outcomes. Current Topics in Microbiology and Immunology. 2017;401:85–92.
   PubMed Web of Science ®Google Scholar
• Okazaki K, Chari ST, Frulloni L, et al., International consensus for the treatment of autoimmune pancreatitis. Pancreatology 17(1): 1–6. 2017. .
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49(6):961–970.
   PubMed Web of Science ®Google Scholar
• Buijs J, Van Heerde MJ, Rauws EAJ, et al. Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. Pancreas 2014;43(2):261–267.
   PubMed Web of Science ®Google Scholar
• Wu Q, Chang J, Chen H, et al. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: a preliminary randomized controlled trial. International Journal of Rheumatic Diseases. 2017;20(5):639–646.
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Campochiaro C, Bozzalla Cassione E, et al. Intrathecal rituximab for IgG 4 -related hypertrophic pachymeningitis. Journal of Neurology, Neurosurgery & Psychiatry. 2018;89(4):441–444.
   PubMed Web of Science ®Google Scholar
• Masaki Y, Matsui S, Saeki T, et al. A multicenter phase II prospective clinical trial of glucocorticoid for patients with untreated IgG4-related disease. Modern Rheumatology. 2017;27(5):849–854.
   PubMed Web of Science ®Google Scholar
• Kubota K, Kamisawa T, Okazaki K, et al. Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients. Journal of Gastroenterology. 2017;52(8):955–964.
   PubMed Web of Science ®Google Scholar
• Omar D, Chen Y, Cong Y, et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. Rheumatology (Oxford). 2019;kez380. DOI:10.1093/rheumatology/kez380.
   Web of Science ®Google Scholar
• Wang Y, Li K, Gao D, et al. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review. Internal Medicine Journal. 2017;47(6):680–689.
   PubMed Web of Science ®Google Scholar
• Yunyun F, Yu P, Panpan Z, et al. Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology (Oxford). 2019;58(1):52–60.
   PubMed Web of Science ®Google Scholar
• Yunyun F, Yu C, Panpan Z, et al. Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Scientific Reports. 2017;7(1):6195.
   PubMedGoogle Scholar
• Buechter M, Klein CG, Kloeters C, et al. Tacrolimus as a Reasonable Alternative in a Patient with Steroid-Dependent and Thiopurine-Refractory Autoimmune Pancreatitis with IgG4-Associated Cholangitis. Z Gastroenterol. 2014;52(6):564–568.
   PubMed Web of Science ®Google Scholar
• De Pretis N, Amodio A, Bernardoni L, et al. Azathioprine Maintenance Therapy to Prevent Relapses in Autoimmune Pancreatitis. Clin Transl Gastroenterol. 2017;8(4):e90.
   PubMedGoogle Scholar
• Hart PA, Topazian MD, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013;62(11):1607–1615.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Y, Bian W, et al. Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease. Clin Rheumatol. 2020;39(2):491–497.
   PubMed Web of Science ®Google Scholar
• Zhang P, Gong Y, Liu Z, et al. Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: a prospective clinical trial. Int J Rheum Dis. 2019;22(8):1479–1488.
   PubMed Web of Science ®Google Scholar
• Rovati L, Lanzillotta M, Bozzolo E, et al. Methotrexate as induction of remission therapy for type 1 autoimmune pancreatitis. American Journal of Gastroenterology. 2019;114(5):831–833.
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Campochiaro C, Bozzolo EP, et al. Methotrexate for maintenance of remission in IgG4-related disease: fig. 1. Rheumatology (Oxford). 2015;54(10):1934–1936. .
   PubMed Web of Science ®Google Scholar
• Culver EL, Sadler R, Bateman AC, et al. Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clinical Gastroenterology and Hepatology. 2017;15(9):e6.
   Web of Science ®Google Scholar
• Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009;58(11):1504–1507.
   PubMed Web of Science ®Google Scholar
• Masamune A, Nishimori I, Kikuta K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis. Gut 2017;66(3):487–494.
   PubMed Web of Science ®Google Scholar
• Luo X, Peng Y, Zhang P, et al. Comparison of the Effects of Cyclophosphamide and Mycophenolate Mofetil Treatment Against Immunoglobulin G4-Related Disease: a Retrospective Cohort Study. Frontiers in Medicine. 2020;7:253.
   PubMed Web of Science ®Google Scholar
• Stone JH, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis & Rheumatism. 2012;64(10):3061–3067. .
   PubMed Web of Science ®Google Scholar
• Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. Nature Reviews Rheumatology. 2020;16(12):702–714.
   PubMed Web of Science ®Google Scholar
• Lanzillotta M, Della-Torre E, Milani R, et al. Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease. Clin Exp Rheumatol. 2019;37 Suppl 118(Suppl 3):159–166.
   PubMed Web of Science ®Google Scholar
• Doorenspleet ME, Hubers LM, Culver EL, et al. Immunoglobulin G4 + B-cell receptor clones distinguish immunoglobulin G 4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies. Hepatology 2016;64(2):501–507.
   PubMed Web of Science ®Google Scholar
• Lanzillotta M, Della-Torre E, Milani R, et al. Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse. Arthritis Research & Therapy. 2018;20(1):222. .
   PubMedGoogle Scholar
• Della-Torre E, Bozzalla-Cassione E, Sciorati C, et al. A CD8α− Subset of CD4+SLAMF7+ Cytotoxic T Cells Is Expanded in Patients With IgG4-Related Disease and Decreases Following Glucocorticoid Treatment. Arthritis & Rheumatology. 2018;70(7):1133–1143.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Yajima T, Shimaoka T, et al. Synergistic effect of IgG4 antibody and CTLs causes tissue inflammation in IgG4-related disease. International Immunology. 2020;32(3):163–174.
   PubMed Web of Science ®Google Scholar
• Perugino CA, AlSalem SB, Mattoo H, et al. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. J Allergy Clin Immunol. 2019;143(2):e6. .
   Web of Science ®Google Scholar
• Shiokawa M, Kodama Y, Kuriyama K, et al. Pathogenicity of IgG in patients with IgG4-related disease. Gut 2016;65(8):1322–1332. .
   PubMed Web of Science ®Google Scholar
• Khosroshahi A, Bloch DB, Deshpande V, et al., Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis & Rheumatism. 62(6): 1755–1762. 2010. .
   PubMed Web of Science ®Google Scholar
• Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012;91(1):57–66. .
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Annals of the Rheumatic Diseases. 2015;74(1):190–195. .
   PubMed Web of Science ®Google Scholar
• Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: data from a French nationwide study of thirty-three patients. PLoS One. 2017;12(9):e0183844. .
   PubMed Web of Science ®Google Scholar
• Majumder S, Mohapatra S, Lennon RJ, et al. Rituximab maintenance therapy reduces rate of relapse of pancreaticobiliary Immunoglobulin G4-related disease. Clin Gastroenterol Hepatol. 2018;16(12):1947–1953.
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Conti A, Berti A, et al. Rituximab hypersensitivity in IgG4-related disease: successful desensitization in a patient with IgG4 rheumatoid factor. International Journal of Rheumatic Diseases. 2017;20(2):276–279.
   PubMed Web of Science ®Google Scholar
• Carruthers MN, Topazian MD, Khosroshahi A, et al., Rituximab for IgG4-related disease: a prospective, open-label trial. Annals of the Rheumatic Diseases. 74(6): 1171–1177. 2015. .
   PubMed Web of Science ®Google Scholar
• Fernández-Codina A, Orozco-Gálvez O, Therapeutic M-VF. Options in IgG4-Related Disease. Curr Treat Options Rheumatol. 2021. In press.
   Google Scholar
• Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener’s granulomatosis: modification of the Birmingham Vasculitis Activity Score. Arthritis & Rheumatism. 2001;44(4):912–920. .
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Lanzillotta M, Campochiaro C, et al. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. Eur J Intern Med. 2020;S0953-6205(20):30449.
   Google Scholar
• Campochiaro C, Della-Torre E, Lanzillotta M, et al. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. Eur J Intern Med. 2020;74:92–98.
   PubMed Web of Science ®Google Scholar
• Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD) - Full Text View - ClinicalTrials.gov [Internet]. [ cited 2020 Dec 12]. Available from:https://clinicaltrials.gov/ct2/show/study/NCT02725476
   Google Scholar
• Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. The Lancet. 2019;394(10206):1352–1363. .
   PubMed Web of Science ®Google Scholar
• A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease - Full Text View-ClinicalTrials.gov. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04540497
   Google Scholar
• Wen T, Wang J, Shi Y, et al. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia. 2021;35(2):312–332.
   Web of Science ®Google Scholar
• Open Label Two-Arm Study to Evaluate Rilzabrutinib (PRN1008) in IgG4-Related Disease Patients - Tabular View - ClinicalTrials.gov [Internet]. 2020. [ cited 2020 Dec 12]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT04520451
   Google Scholar
• Zanubrutinib in Patients With IgG 4-Related Disease - Full Text View - ClinicalTrials.gov [Internet]. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT0460259880.
   Google Scholar
• Khan ML, Colby TV, Viggiano RW, et al. Treatment with bortezomib of a patient having hyper IgG4 disease. Clinical Lymphoma Myeloma and Leukemia. 2010;10(3):217–219.
   PubMed Web of Science ®Google Scholar
• Treatment of IgG4-Related Disease With Revlimid and Rituximab - Full Text View - ClinicalTrials.gov [Internet]. 2016. Available from: https://clinicaltrials.gov/ct2/show/NCT02705638
   Google Scholar
• Della Torre E, Mattoo H, Mahajan VS, et al. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease. Allergy 2014;69(2):269–272. .
   PubMed Web of Science ®Google Scholar
• Mattoo H, Della-Torre E, Mahajan VS, et al. Circulating Th2 memory cells in IgG4-related disease are restricted to a defined subset of subjects with atopy. Allergy 2014;69(3):399–402. .
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Takahashi H, Takano K, et al. Efficacy of abatacept for IgG4-related disease over 8 months. Annals of the Rheumatic Diseases. 2016;75(8):1576–1578. .
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. for the ELOQUENT-2 investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631. .
   PubMed Web of Science ®Google Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Critical Reviews in Oncology/Hematology. 2013;88(1):168–177.
   PubMed Web of Science ®Google Scholar
• US Department of Health & Human Services. Research Portfolio Online Reporting Tools(RePORT). 2020. Available from: https://projectreporter.nih.gov/project_info_description.cfm?aid=9731061&icde=44650655 .
   Google Scholar
• Alegria GC, Pochard P, Pers J-O, et al. Could abatacept directly target expanded plasmablasts in IgG4-related disease? Annals of the Rheumatic Diseases. 2016;75(11):e73. .
   PubMed Web of Science ®Google Scholar
• Cheng LE, Amoura Z, Cheah B, et al. Brief Report: a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis & Rheumatology. 2018;70(7):1071–1076. .
   PubMed Web of Science ®Google Scholar
• Zhang M, Lee F, Knize A, et al. Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clinical and Experimental Rheumatology. 2019;37(6):906–914.
   PubMed Web of Science ®Google Scholar
• Rangal KM, Reighard SD, Ochayon DE, et al. Cell therapy targeting follicular T cells as an innovative approach for treating autoimmune disease. J Immunol. 2020;204:236, 9
   Web of Science ®Google Scholar
• Zen Y, Fujii T, Harada K, et al. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Hepatology 2007;45(6):1538–1546. .
   PubMed Web of Science ®Google Scholar
• Tanaka A, Moriyama M, Nakashima H, et al. Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease. Arthritis & Rheumatism. 2012;64(1):254–263. .
   PubMed Web of Science ®Google Scholar
• Heeringa JJ, Karim AF, Van Laar JAM, et al. Expansion of blood IgG 4 + B, T H 2, and regulatory T cells in patients with IgG 4 -related disease. J Allergy Clin Immunol. 2018;141(5):e10. .
   Web of Science ®Google Scholar
• Simpson RS, Lau SKC, Lee JK. Dupilumab as a novel steroid-sparing treatment for IgG4-related disease. Annals of the Rheumatic Diseases. 2020;79(4):549–550.
   PubMed Web of Science ®Google Scholar
• Ebbo M, De Sainte-Marie B, Muller R, et al. Comment on article: ‘Dupilumab as a novel steroid-sparing treatment for IgG 4 -related disease’ by Simpson et al. Ann Rheum Dis. 2020;annrheumdis-2020-217010. annrheumdis-2020-217010. 10.1136/annrheumdis-2020-217010.
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Lanzillotta M, Yacoub M-R. Dupilumab as a potential steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis. 2020:annrheumdis-2020-216945 annrheumdis-2020-216945. 10.1136/annrheumdis-2020-216945.
   Web of Science ®Google Scholar
• Maehara T, Mattoo H, Ohta M, et al. Lesional CD4 + IFN-γ + cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Annals of the Rheumatic Diseases. 2017;76(2):377–385. .
   PubMed Web of Science ®Google Scholar
• Capecchi R, Italiani P, Puxeddu I, et al. IL-1 family cytokines and receptors in IgG4-related disease. Cytokine 2018;102:145–148.
   PubMed Web of Science ®Google Scholar
• Hong X, Min SN, Zhang YY, et al. TNF-α Suppresses Autophagic Flux in Acinar Cells in IgG4-Related Sialadenitis. Journal of Dental Research. 2019;98(12):1386–1396. .
   PubMed Web of Science ®Google Scholar
• Karim F, Paridaens D, Westenberg LEH, et al. Infliximab for IgG4-Related Orbital Disease. Ophthalmic Plastic & Reconstructive Surgery. 2017;33(3S):S162–S165. .
   PubMedGoogle Scholar
• Jalaj S, Dunbar K, Campbell A, et al. Treatment of Pediatric IgG4-Related Orbital Disease With TNF-α Inhibitor. Ophthalmic Plastic & Reconstructive Surgery. 2018;34(1):e10–e12. .
   PubMed Web of Science ®Google Scholar
• Maehara T, Moriyama M, Nakashima H, et al. Interleukin-21 contributes to germinal centre formation and immunoglobulin G4 production in IgG4-related dacryoadenitis and sialoadenitis, so-called Mikulicz’s disease. Annals of the Rheumatic Diseases. 2012;71(12):2011–2020. .
   PubMed Web of Science ®Google Scholar
• Akiyama K, Kawabata D, Hosono Y, et al. Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance. Arthritis Research & Therapy. 2012;14(2):R86. .
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Aochi S, Suzuki C, et al. A case with good response to belimumab for lupus nephritis complicated by IgG4-related disease. fur Lupus. 2019;28(6):786–789.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang P, Li J, et al. Different clinical patterns of IgG4-RD patients with and without eosinophilia. Scientific Reports. 2019;9(1):16483. .
   PubMedGoogle Scholar
• Yamamoto M, Takano K-I, Kamekura R, et al. Interleukin 5-producing ST2 + memory Th2 cells in IgG4-related dacryoadenitis and sialadenitis. Modern Rheumatology. 2019;29(5):856–860. .
   PubMed Web of Science ®Google Scholar
• Moussiegt A, Muller R, Ebbo M, et al. IgG4-Related Disease and Hypereosinophilic Syndrome: overlapping Phenotypes? Poster presented at the 11th biennial symposium of the international eosinophil society; 2019 Jul 9–13. Portland, Oregon, USA.
   Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery. 2018;17(1):78. .
   Web of Science ®Google Scholar
• Khan S, Gordins P, Durairaj S. JAK inhibition as a therapeutic strategy for IgG4-RD. J Investig Allergol Clin Immunol. 2020;25.
   Google Scholar
• Lescoat A, Lelong M, Jeljeli M, et al. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease. Biochemical Pharmacology. 2020;178:114103.
   PubMed Web of Science ®Google Scholar